CXCR4 expression is associated with survival in familial chronic lymphocytic leukemia, but CD38 expression is not by Naoko Ishibe, Maher Albitar, Iman.

Slides:

Advertisements

Similar presentations

Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival by Nathalie A. Johnson, Merrill Boyle, Ali Bashashati, Stephen.

Advertisements

Lymphoma dissemination: the other face of lymphocyte homing by Steven T. Pals, David J. J. de Gorter, and Marcel Spaargaren Blood Volume 110(9):

Telomere dysfunction and fusion during the progression of chronic lymphocytic leukemia: evidence for a telomere crisis by Thet Thet Lin, Boitelo T. Letsolo,

Quantitative modeling of chronic myeloid leukemia: insights from radiobiology by Tomas Radivoyevitch, Lynn Hlatky, Julian Landaw, and Rainer K. Sachs Blood.

MicroRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia by Daniela Asslaber, Josefina.

Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia by Natali Pflug, Jasmin Bahlo, Tait D. Shanafelt, Barbara.

Stem cell concepts renew cancer research by John E. Dick Blood Volume 112(13): December 15, 2008 ©2008 by American Society of Hematology.

Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas by Amrita Krishnan, Arturo Molina, John Zaia, David.

Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia by Alessandra Ferrajoli,

Hairy Cell Leukemia Variant Has Similar Survival to Classical Disease Despite Poorer Responses to Initial Therapy: A 30-Year Experience from Memorial Sloan.

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,

Investigating a New Methodology for the Detection of Low Frequency 17p Deleted Clones in Chronic Lymphocytic Leukaemia (CLL): Impact on Prognostic Outcome.

The clinical significance of tumor necrosis factor-α plasma level in patients having chronic lymphocytic leukemia by Alessandra Ferrajoli, Michael J. Keating,

by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E

Alternate designs for conduct and analysis of phase I cancer trials

MBL: mostly benign lymphocytes, but…

Whole exome sequencing in families with CLL detects a variant in Integrin β 2 associated with disease susceptibility by Lynn R. Goldin, Mary L. McMaster,

Fledgling prognostic markers in CLL

by Susan L. Slager, Kari G. Rabe, Sara J. Achenbach, Celine M

Next-generation leukemia immunotherapy

Dasatinib induces complete remission in a patient with primary cerebral involvement of B-cell chronic lymphocytic leukemia failing chemotherapy by Georg.

Analysis of expressed immunoglobulin heavy chain genes in familial B-CLL by Akira Sakai, Gerald E. Marti, Neil Caporaso, Stefania Pittaluga, Jeffrey W.

Outcomes in Patients with Chronic Myeloid Leukemia (CML) Who Are Treated with Imatinib As Front Line Therapy by Kendra L. Sweet, Najla H Al Ali, Jeffrey.

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants by.

Mohamed A. Kharfan-Dabaja, Claudio Anasetti, Edgardo S. Santos

Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response by Andreas Rosenwald, Eric Y. Chuang,

Rituximab-induced tumor cell agglutination

Tax fingerprint in adult T-cell leukemia

A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia by John C. Byrd, Guido Marcucci,

How I treat elderly patients with myeloma

Symptomatic and Incidental Venous Thromboembolic Disease Are Both Associated With Mortality In Patients With Prostate Cancer by Shruti Chaturvedi, Surbhi.

Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib by Preetesh Jain, Michael Keating, William Wierda, Zeev Estrov, Alessandra.

Mechanisms of HIV-associated lymphocyte apoptosis

The Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Promotes High Response Rate, Durable Remissions, and Is Tolerable in Treatment Naïve.

by Petri Salven, Lasse Teerenhovi, and Heikki Joensuu

Autologous Transplantation Therapy for Chronic Myelogenous Leukemia

by Romina Gamberale, Jorge R. Geffner, Julieta Sanjurjo, Paula X

What is a true ALCL? by Wolfram Klapper Blood Volume 124(9):

CD6 Ligation Modulates the Bcl-2/Bax Ratio and Protects Chronic Lymphocytic Leukemia B Cells From Apoptosis Induced by Anti-IgM by Lyda M. Osorio, Angelina.

Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia.

Plasma thrombopoietin compared with immunoglobulin heavy-chain mutation status as a predictor of survival in chronic lymphocytic leukemia by Charles Koller,

Acute promyelocytic leukemia, microgranular variant

An actuarial GPS for hemophilic longevity

Detection of Trisomy 12 and Rb-Deletion in CD34+ Cells of Patients With B-Cell Chronic Lymphocytic Leukemia by B. Gahn, C. Schäfer, J. Neef, C. Troff,

Relative increase in leukemia-specific DNA in peripheral blood plasma from patients with acute myeloid leukemia and myelodysplasia by Anna Rogers, Youngson.

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

Long-Lasting Responses with Lenalidomide As Initial Therapy of Elderly Patients with Chronic Lymphocytic Leukemia (CLL)‏ by Paolo Strati, Michael J. Keating,

by Paolo Strati, Michael J. Keating, William G. Wierda, Xavier C

Accurate quantification of minimal residual disease at day 15, by real-time quantitative polymerase chain reaction identifies also patients with B-precursor.

Stage C or not stage C…? by Claire Dearden Blood

How I treat refractory CLL

LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B-cell lymphocytosis by Albert Gutierrez,

Anergy: the CLL cell limbo

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.

by Martin S. Tallman, Donna Neuberg, John M. Bennett, Christopher J

BET Bromodomain Inhibition Reduces Leukemic Burden and Prolongs Survival In The Eμ-TCL1 Transgenic Mouse Model Of Chronic Lymphocytic Leukemia (CLL) Independent.

Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia by Philip.

Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia.

by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc

High Levels of Circulating HSP70 Levels in Patients with Chronic Myeloid Leukemia and Correlation with Resistance to Therapy with Imatinib. by Richard.

Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.

Biology and treatment of Richter syndrome

Mary Eapen Biology of Blood and Marrow Transplantation

Evaluation of the International Prognostic Index for Chronic Lymphocytic Leukemia (CLL-IPI) in Elderly Patients with Comorbidities: Analysis of the CLL11.

Initial treatment of CLL: integrating biology and functional status

Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia

Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance by Taghi Manshouri, Kim-anh.

by Victor A. Chow, Mazyar Shadman, and Ajay K. Gopal

Cold agglutinin disease

Presentation transcript:

CXCR4 expression is associated with survival in familial chronic lymphocytic leukemia, but CD38 expression is not by Naoko Ishibe, Maher Albitar, Iman B. Jilani, Lynn R. Goldin, Gerald E. Marti, and Neil E. Caporaso Blood Volume 100(3):1100-1101 August 1, 2002 ©2002 by American Society of Hematology

Survival probabilities for familial CLL patients Survival probabilities for familial CLL patients.(A) Survival probabilities comparing CLL patients by CD38 expression pattern. Survival probabilities for familial CLL patients.(A) Survival probabilities comparing CLL patients by CD38 expression pattern. (B) Survival probabilities comparing CLL patients by CXCR4 expression pattern. Naoko Ishibe et al. Blood 2002;100:1100-1101 ©2002 by American Society of Hematology